Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years

Cancer

Volumn 121, Issue 22, 2015, Pages 4062-4070

  Potosky, Arnold L ^a   O'Neill, Suzanne C ^a   Isaacs, Claudine ^a   Tsai, Huei Ting ^a   Chao, Calvin ^b   Liu, Chunfu ^c   Ekezue, Bola F ^c   Selvam, Nandini ^c   Kessler, Larry G ^d   Zhou, Yingjun ^a   Schwartz, Marc D ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b Genomic Health Inc   (United States)

^c HEALTHCORE INC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

breast neoplasms; chemotherapy; gene expression profiling; population based studies; practice patterns

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; EARLY CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; UNITED STATES; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; GENETICS; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 84946492230     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29621     Document Type: Article

References (26)

1. Mamounas EP, Tang G, Fisher B, et al., Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010; 28: 1677-1683.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast cancer. Version 1.2012. http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed March 7, 2012.
3. Harris L, Fritsche H, Mennel R, et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312.
4. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
5. Partridge AH, Winer EP,. Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Dis. 2004; 21: 55-64.
6. Paik S, Tang G, Shak S, et al., Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3726-3734.
7. Lyman GH, Cosler LE, Kuderer NM, Hornberger J,. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007; 109: 1011-1018.
8. Zanotti L, Bottini A, Rossi C, Generali D, Cappelletti MR,. Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. Tumour Biol. 2014; 35: 8461-8470.
9. Paik S, Shak S, Tang G, et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826.
10. Jerevall PL, Brommesson S, Strand C, et al., Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat. 2008; 107: 225-234.
11. Kelly CM, Krishnamurthy S, Bianchini G, et al., Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010; 116: 5161-5167.
12. Genomic Health, Inc. Will my insurance cover the test? http://breast-cancer.oncotypedx.com/en-US/Patient-DCIS/GettingTested/WillMyInsuranceCoverTheTest.aspx. Accessed March 10, 2015.
13. Carlson JJ, Roth JA,. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013; 141: 13-22.
14. Hassett MJ, Silver SM, Hughes ME, et al., Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012; 30: 2218-2226.
15. National Cancer Institute. Derived HER2 recode (2010+). http://seer.cancer.gov/seerstat/databases/ssf/her2-derived.html. Accessed July 2015.
16. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 8-27.
17. Ben-Baruch N, Hammerman A, Klang S, Liebermann N,. A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early stage breast cancer patients [abstract 1108]. J Clin Oncol. 2007; 25: 1108.
18. Nixon AJ, Neuberg D, Hayes DF, et al., Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994; 12: 888-894.
19. Lund MJ, Mosunjac M, Davis KM, et al., 21-gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer. 2012; 118: 788-796.
20. Mamounas EP, Tang G, Paik S, et al., Prognostic impact of the 21-gene recurrence score in disease-free and overall survival of node-positive breast cancer patients treated with adjuvant chemotherapy: results from NSABP B-28 [abstract]. J Clin Oncol. 2012; 30 (suppl 27): 1.
21. Penault-Llorca M, Filleron T, Asselain B, et al., Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: results from PACS01 trial. J Clin Oncol. 2014; 32: 5s.
22. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al., Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2013; 34: 1-9.
23. Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW,. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol. 2009; 99: 319-323.
24. Oratz R, Paul D, Cohn A, Sedlacek S,. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract. 2007; 3: 182-186.
25. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ,. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003; 21: 3357-3365.
26. Silliman RA, Ganz PA,. Adjuvant chemotherapy use and outcomes in older women with breast cancer: what have we learned? J Clin Oncol. 2006; 24: 2697-2699.